---
title: "Intellia Temporarily Pauses Dosing For MAGNITUDE And MAGNITUDE-2 Phase 3 Clinical Trials Of Nex-z"
description: "Intellia Therapeutics, Inc. (NTLA) has temporarily paused patient dosing and screening for its MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials of nex-z due to a report of serious liver issues in a p"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262890110.md"
published_at: "2025-10-27T11:54:27.000Z"
---

# Intellia Temporarily Pauses Dosing For MAGNITUDE And MAGNITUDE-2 Phase 3 Clinical Trials Of Nex-z

> Intellia Therapeutics, Inc. (NTLA) has temporarily paused patient dosing and screening for its MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials of nex-z due to a report of serious liver issues in a patient. The company is consulting with experts and regulatory authorities while monitoring the situation. Currently, over 650 patients with transthyretin amyloidosis are enrolled in the trials, with more than 450 having been dosed with nex-z.

Gene editing company Intellia Therapeutics, Inc. (NTLA) announced Monday that the company has temporarily paused patient dosing and screening for its MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials of nex-z for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN), respectively.

This action follows a report on October 24, 2025 of Grade 4 liver transaminases and increased total bilirubin in a patient who was dosed with nex-z in the MAGNITUDE trial on September 30, 2025, meeting the trial's protocol-defined pausing criteria.

The patient was hospitalized, is being closely monitored and is receiving medical intervention. Intellia is consulting with experts, considering potential risk mitigation strategies and engaging with regulatory authorities.

As of today, more than 650 patients with ATTR-CM are enrolled in MAGNITUDE, and 47 patients with ATTR-PN are enrolled in MAGNITUDE-2. Over 450 of these patients are estimated to have been dosed with nex-z.

For comments and feedback contact: editorial@rttnews.com

Business News

### Related Stocks

- [NTLA.US - Intellia Therap](https://longbridge.com/en/quote/NTLA.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Buy Rating for Intellia Therapeutics: Promising Long-Term Data and Market Potential for nex-z in ATTR-PN Treatment | Debanjana Chatterjee has issued a Buy rating for Intellia Therapeutics, citing promising long-term data from the Phase 1 | [Link](https://longbridge.com/en/news/258972081.md) |
| Cathie Wood Keeps Loading Up on This Biotech Stock — What's Driving the Steady Buying? | Cathie Wood's ARK Invest continues to buy shares of Intellia Therapeutics (NTLA), showing confidence in the company's lo | [Link](https://longbridge.com/en/news/272504828.md) |
| Intellia Therapeutics VP and Chief Accounting Officer Michael P. Dube Reports Disposal of Common Shares | Michael P. Dube, VP and Chief Accounting Officer of Intellia Therapeutics Inc., reported the disposal of common shares.  | [Link](https://longbridge.com/en/news/271836744.md) |
| Mitchell Kapoor Maintains Buy Rating on Intellia Therapeutics Despite Market Overreaction to Phase 3 Trial Pause | Mitchell Kapoor maintains a Buy rating on Intellia Therapeutics, arguing that the market's negative reaction to the Phas | [Link](https://longbridge.com/en/news/262935992.md) |
| Intellia Reports Favorable Phase 1 Data for Nex-Z | Intellia Therapeutics (NTLA) announced positive Phase 1 data for nexiguran ziclumeran (nex-z) in transthyretin amyloidos | [Link](https://longbridge.com/en/news/265226783.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.